Immunoglobulin DNA cassette molecules, monobody constructs, methods of production, and methods of use therefor

• US 7,053,202 B2
• Filed: 10/17/2002
• Issued: 05/30/2006
• Est. Priority Date: 10/19/2001
• Status: Active Grant

• Current Assignee: Takeda Pharmaceutical Company Limited
• Original Assignee: Millennium Pharmaceuticals Incorporated (Takeda Pharmaceutical Company Limited)
• Inventors: O'Keefe, Theresa L., Ponath, Paul D.
• Primary Examiner(s): Nickol, Gary
• Assistant Examiner(s): AEDER, SEAN E
• Application Number:
  US10/272,899
• Publication Number:
  US 20040033561A1
• Time in Patent Office: 1,321 Days
• Field of Search: 514/44, 530/387.3, 536/23.53, 536/23.1, 435/320.1
• US Class Current: 536/23.53
• CPC Class Codes: C07H 21/04 with deoxyribosyl as saccharide radical
• CPC Class Codes: C07K 16/00 Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies antibodies with enzymatic activity, e.g. abzymes C12N9/0002
• CPC Class Codes: C07K 16/2866 against receptors for cytokines, lymphokines, interferons
• CPC Class Codes: C07K 2317/24 containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
• CPC Class Codes: C07K 2319/00 Fusion polypeptide

Abstract

Featured are DNA molecules, expression vectors, and host cells useful for creation of immunoglobulins, as well as novel immunoglobulin molecules termed monobodies. Additionally provided are methods of production of immunoglobulins, including monobodies, as well as methods of using the disclosed immunoglobulin and monobody constructs, expression vectors and host cells containing DNA encoding molecules for production of immunoglobulin and monobody proteins.

Claims

1. A DNA expression vector comprising a nucleic acid sequence encoding a human IgG1 heavy chain constant region sequence of SEQ ID NO:

10, and a nucleic acid sequence encoding a humanized 1D9 heavy chain variable region.

2. The expression vector of claim 1, further comprising a nucleic acid sequence encoding a human light chain constant region.

3. The expression vector of claim 2, wherein the human light chain constant region is a kappa light chain constant region.

4. The expression vector of claim 1, further comprising a nucleic acid sequence encoding a humanized 1D9 light chain variable region.

5. The expression vector of claim 4, further comprising a nucleic acid sequence encoding a human light chain constant region.

6. The expression vector of claim 5, wherein the human light chain constant region is a kappa light chain constant region.

7. The expression vector of claim 1, wherein the nucleic acid sequence comprises the heavy chain constant region encoding nucleotide sequence of SEQ ID NO:

9.

8. The expression vector of claim 3 or claim 6, wherein the nucleic acid sequence encodes the light chain constant region sequence of SEQ ID NO:

12.

9. The expression vector of claim 8, wherein the nucleic acid sequence comprises the light chain constant region encoding nucleotide sequence of SEQ ID NO:

11.

10. The expression vector of claim 1, wherein the nucleic acid sequence encoding the heavy chain constant region and the nucleic acid encoding the humanized heavy chain variable region are operably linked to a promoter selected from the group consisting of a EF-1a promoter, a CMV promoter, an SV40 promoter, and an adenovirus major late promoter.

11. The expression vector of claim 10, wherein the promoter is a EF-1a promoter.

12. The expression vector of claim 11, wherein the nucleic acid sequence encoding the heavy chain constant region and the nucleic acid sequence encoding the humanized heavy chain variable region are under control of the same promoter.

13. The expression vector of claim 11 or claim 12, wherein the vector further comprises a BGH poly A sequence.

14. The expression vector of claim 13, wherein the BGH polyA sequence is downstream from the sequence encoding the heavy chain constant region.

15. The expression vector of claim 1, further comprising a selectable marker gene.

16. The expression vector of claim 15, wherein the selectable marker gene is selected from the group consisting of a dihydrofolate reductase (DHFR) gene and a neo gene.

17. The expression vector of claim 1, wherein the expression vector comprises at least two marker genes and the marker genes are a DHFR gene and a neo gene.

18. The expression vector of claim 1, wherein the nucleic acid sequence encoding the heavy chain constant region further comprises an immunoglobulin leader sequence.

19. The expression vector of claim 3 or claim 6, wherein the nucleic acid sequence encoding the light chain constant region further comprises an immunoglobulin leader sequence.

20. The expression vector of claim 1, wherein the nucleic acid sequence encoding the humanized heavy chain variable region further comprises an immunoglobulin leader sequence.

21. The expression vector of claim 4 or claim 6, wherein the nucleic acid sequence encoding the humanized light chain variable region further comprises an immunoglobulin leader sequence.

32. A host cell comprising the expression vector of claim 1 or claim 22.

33. The cell of claim 32, wherein the cell is selected from the group consisting of a bacterial, a yeast and a mammalian cell.

34. The cell of claim 33, wherein the cell is a mammalian cell.

35. The cell of claim 34, wherein the mammalian cell is selected from the group consisting of a lymphocytic cell line, CHO, and COS cells.

36. The cell of claim 34, wherein the mammalian cell is a CHO cell.

37. The cell of claim 36, wherein the CHO cell is a DHFR deficient CHO cell.

22. A DNA expression vector comprising a nucleic acid sequence encoding the heavy chain constant region sequence of SEQ ID NO:

10, a nucleic acid sequence encoding a humanized 1D9 heavy chain variable region, a nucleic acid encoding the light chain constant region sequence of SEQ ID NO;

12, and a nucleic acid sequence encoding a humanized 1D9 light chain variable region.

23. The expression vector of claim 22, wherein the nucleic acid sequence encoding the heavy chain constant region and the nucleic acid sequence encoding the humanized heavy chain variable region are operably linked to an EF-1a promoter.

24. The expression vector of claim 22, wherein the nucleic acid sequence encoding the light chain constant region and the nucleic acid sequence encoding the humanized light chain variable region are operably linked to an EF-1a promoter.

25. The expression vector of claim 23, wherein the nucleic acid sequence encoding the light chain constant region and the nucleic acid sequence encoding the humanized light chain variable region are operably linked to an EF-1a promoter.

26. The expression vector of claim 22, claim 23, claim 24 or claim 25, wherein the vector further comprises a BGH poly A sequence.

27. The expression vector of claim 26, wherein the BGH polyA sequence is downstream from the sequence encoding the heavy chain constant region.

28. The expression vector of claim 22, further comprising a selectable marker gene.

29. The expression vector of claim 28, wherein the selectable marker is selected from the group consisting of a DHFR gene and a neo gene.

30. The expression vector of claim 22, wherein the nucleic acid encoding the humanized heavy chain variable region further comprises an immunoglobulin leader sequence.

31. The expression vector of claim 22, wherein the nucleic acid sequence encoding the humanized light chain variable region further comprises an immunoglobulin leader sequence.